Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. [electronic resource] by
- Rudin, Charles M
- Pietanza, M Catherine
- Bauer, Todd M
- Ready, Neal
- Morgensztern, Daniel
- Glisson, Bonnie S
- Byers, Lauren A
- Johnson, Melissa L
- Burris, Howard A
- Robert, Francisco
- Han, Tae H
- Bheddah, Sheila
- Theiss, Noah
- Watson, Sky
- Mathur, Deepan
- Vennapusa, Bharathi
- Zayed, Hany
- Lally, Satwant
- Strickland, Donald K
- Govindan, Ramaswamy
- Dylla, Scott J
- Peng, Stanford L
- Spigel, David R
Producer: 20170613
In:
The Lancet. Oncology vol. 18
Availability: No items available.
|